Stock Market Reviews

Read and share opinions on MRNA (Moderna, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
  Dec 30, 2025
• Moderna (MRNA) Stock Dips While Market Gains: Key Facts
  Dec 23, 2025
• Why Is Moderna (MRNA) Stock Rocketing Higher Today
  Dec 19, 2025
• MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
  Dec 19, 2025
• Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding
  Dec 18, 2025
• Moderna, Inc. (MRNA): A Bull Case Theory
  Dec 18, 2025
• Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
  Dec 18, 2025
• Why Moderna (MRNA) Stock Is Up Today
  Dec 18, 2025
• Moderna (MRNA) Stock Trades Up, Here Is Why
  Dec 17, 2025
• Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
  Dec 17, 2025

MRNA News

• Forget Moderna Stock, This is a Much Better Buy
  This stock is a great choice for cautious and aggressive investors.
  Dec 27, 2025
• A Watching-the-Paint-Dry Stock Market, and Why Volatility Will Make a Comeback
  It’s been a “low volatility holiday season,” according to Citigroup strategists, but don’t expect it to stay that way heading into 2026. The S&P 500 is down 0.1%, while the Dow Jones Industrial Average is down 0.2%, and the Nasdaq Composite is little changed. The CBOE Volatility Index, or VIX, is still trading below 14, though it has ticked up a touch today.
  Dec 26, 2025
• Moderna Stock Sees Healthy Relative Strength Rating
  Moderna stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 67 to 73. See if Moderna stock can continue to rebound and clear that threshold. Moderna stock tried to breakout of a cup-shaped base on Dec. 22, but has pulled back slightly.
  Dec 26, 2025
• These Stocks Are Moving the Most Today: Nvidia, Apple, Tesla, Coupang, Micron, Lam Research, Newmont, Moderna, and More
  Nvidia is rising after reaching an agreement with AI start-up Groq, while Lam Research stock is on track for a record high.
  Dec 26, 2025
• It's a Risk-Off Day After Christmas on Wall Street
  The day after Christmas is supposed to be one of the better days of the year. It’s not looking like that right now. After trading higher to start the day, the S&P 500 has dipped 0.04%, while the Dow Jones Industrial Average and Nasdaq Composite have slipped 0.
  Dec 26, 2025
• Stocks Down Pre-Bell Ahead of Shortened Trading Session
  The main US stock measures were trending lower in Wednesday's premarket activity as investors prepar
  Dec 24, 2025
• Moderna (MRNA) Stock Dips While Market Gains: Key Facts
  The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.
  Dec 23, 2025
• MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
  Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
  Dec 19, 2025
• Why Is Moderna (MRNA) Stock Rocketing Higher Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.
  Dec 19, 2025
• Down 80%, Should You Buy the Dip on Moderna?
  Your decision on whether to invest now depends to some extent on your investment strategy.
  Dec 19, 2025
• CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
  Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...
  Dec 18, 2025
• Moderna, Inc. (MRNA): A Bull Case Theory
  We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.’s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency […]
  Dec 18, 2025
• Why Moderna (MRNA) Stock Is Up Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.
  Dec 18, 2025
• Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
  With federal funding cut, Moderna finds new backers for its pandemic play--just as mRNA faces a critical test
  Dec 18, 2025
• Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding
  Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna. The CEPI funding has helped extend a short burst of momentum, with Moderna’s 1 month share price return of 23.22 percent contrasting sharply with a 1 year total shareholder return of negative 20.46 percent. This suggests sentiment is improving, but the longer term recovery story is still being...
  Dec 18, 2025
• Moderna gets funding for H5 pandemic influenza vaccine
  The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.
  Dec 18, 2025
• Moderna (MRNA) Stock Trades Up, Here Is Why
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.
  Dec 17, 2025
• Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
  CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast of the presentation ...
  Dec 17, 2025
• Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE Vaccine - Has The Bull Case Changed?
  The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for individuals aged 12 and older, following Phase 3 data showing higher relative efficacy versus Spikevax. This potential EU approval would broaden Moderna’s respiratory vaccine lineup and regional footprint, partly counterbalancing pressure from weakening COVID-19 vaccine...
  Dec 16, 2025
• CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
  CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
  Dec 16, 2025
• ‘Zombie’ biotech buyer Xoma to acquire Generation Bio
  The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.
  Dec 16, 2025
• 3 Cash-Burning Stocks We Steer Clear Of
  Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
  Dec 15, 2025
• EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
  mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the European Union, subject to authorization by the ...
  Dec 15, 2025
• Amazon and 9 More Stocks to Buy for 2026
  Barron’s capitalized on the trends with Alibaba Group Holding Alphabet and ASML Holding as well as other winners, including Citigroup and Uber Technologies in our top 10 picks for 2025. Rounding out the list is pharmaceutical turnaround candidate Bristol Myers Squibb which yields almost 5%.
  Dec 15, 2025
• Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls
  Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls
  Dec 12, 2025
• Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update
  Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp (NYSE:ARES). The company made this announcement as it prepared to unveil strategy updates to analysts later that day. Moderna plans to […]
  Dec 11, 2025
• Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
  Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.
  Dec 11, 2025
• Moderna signs deal worth up to $503m with Nanexa
  Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent dosing.
  Dec 11, 2025
• Moderna (MRNA) Q3 2024 Earnings Call Transcript
  Stéphane Bancel: Thank you, Lavina. In the third quarter of 2024 compared to the first quarter of 2023, we reduced operating expenses by $500 million across cost of sales, RD and SG&A. This figure excludes $1.4 billion of resizing charge in the first quarter of 2023. Stéphane Bancel: This year, the COVID market benefited from U.S. regulatory approval that was 19 days earlier than in 2023.
  Dec 11, 2025
• Moderna (MRNA) Q3 2025 Earnings Call Transcript
  Stéphane Bancel: In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, mRESVIA. Stéphane Bancel: During the quarter, we made good progress across our 3 strategic priorities. For Spikevax, our original COVID vaccine, we received approval in 40 countries for the seasonal 2025-2026 strain update.
  Dec 11, 2025
• Moderna (MRNA) Just Reclaimed the 200-Day Moving Average
  Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
  Dec 8, 2025
• Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
  Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
  Dec 8, 2025
• How Recent Shifts Are Changing the Narrative for Moderna Stock
  Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return amid ongoing debates around execution risk and cash sustainability. Long term revenue growth expectations have also eased from 10.31% to 10.22%, as models balance stronger liquidity and oncology optionality against litigation and pipeline uncertainties. Stay tuned to see how you can track these...
  Dec 7, 2025
• Why Is Moderna (MRNA) Stock Rocketing Higher Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.
  Dec 5, 2025
• 3 Stocks Under $50 That Fall Short
  The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
  Dec 4, 2025
• Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average
  Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
  Dec 4, 2025
• Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
  VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
  Dec 3, 2025
• Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards
  Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...
  Dec 3, 2025
• Company News for Dec 2, 2025
  Companies In The Article Are: SNPS,DIS,CPNG,MRNA
  Dec 2, 2025
• Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
  Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
  Dec 2, 2025
• Vaccine stocks brace for shock waves at this week’s ACIP meeting
  Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.
  Dec 2, 2025
• Tougher FDA Rules on Vaccine Approval Might Change the Case for Investing in Moderna (MRNA)
  Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety and efficacy evidence for vaccine approvals, following reports of child fatalities linked to COVID-19 vaccinations. This regulatory overhaul is expected to increase development hurdles for vaccine makers, posing significant new challenges for Moderna’s ongoing innovation and pipeline expansion. We’ll explore how heightened regulatory scrutiny could shape Moderna’s...
  Dec 2, 2025
• Is Moderna Stock Underperforming the Nasdaq?
  Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.
  Dec 2, 2025
• Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
  MILLBRAE, Calif., December 02, 2025--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with cutting-edge research to accelerate drug discovery, today announced the election of David W. Meline as an independent director effective November 23, 2025. Mr. Meline is the former Chief Financial Officer at Moderna Inc.
  Dec 2, 2025
• Stock Index Futures Gain as Investors Recover Risk Appetite
  December S&P 500 E-Mini futures (ESZ25) are up +0.27%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.39% this morning, signaling a rebound from yesterday’s sell-off on Wall Street as investor risk appetite gradually returns at the start of December, a period that has historically been strong for markets.
  Dec 2, 2025
• Stock market news: Dow, S&P, Nasdaq slip; US big pharma deal with UK, and Bitcoin falters
  December did not start well for the market, with all the major indices in the red. Will the theories urging caution against expecting a Santa Claus rally hold? Well, this is just Day 1, and for some, the Christmas tree decorations are still pending. So let us not entirely give up on the holiday ...
  Dec 2, 2025
• Moderna Falls as FDA Vows to Impose New Vaccine Requirements
  Vinay Prasad, a top FDA official, blamed Covid shots for playing a role in the deaths of 10 children in the memo he sent to agency staff on Friday, which was seen by Bloomberg. Moderna, which produces Covid shots, fell 4.1% at the start of regular trading in New York on Monday.
  Dec 1, 2025
• Vaccine makers fall on FDA memo, Bally's wins bid for NYC casino
  Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the stock hit vaccine makers Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX) are taking on following a memo from the US Food and Drug Administration (FDA); casino operator Bally's (BALY) has won approval to run casinos in New York City; and Somnigroup International's (SGI) $1.6 billion offer to acquire Leggett & Platt (LEG). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Dec 1, 2025
• Shares of vaccine makers drop after FDA memo flags reports of child deaths
  Investing.com -- Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child deaths linked to heart inflammation.
  Dec 1, 2025
• Moderna Falls As FDA Vows To Impose New Vaccine Rules
  Moderna falls after the Food and Drug Administration said in a memo last week it would place new restrictions on which vaccines hit the market. Bloomberg News reporter Gerry Smith discussed the story on "Bloomberg Markets" with Katie Greifeld.
  Dec 1, 2025
• IDWeek: Annual Meeting 2025 Highlights - Emerging Trends in Prophylactic or Therapeutic Strategies for the Management of Viral, Bacterial, and Fungal Infections
  Emerging market opportunities include advanced therapies for RSV, COVID-19, UTIs, HIV, and fungal infections, with promising candidates such as Moderna's mRNA assets, GSK's TBP-PI-HBr, and Armata's AP-SA02. Focus on innovative strategies in viral, bacterial, and fungal infection management.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "IDWeek: Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering.IDWeek is the joint annual meeting of the Infectious Diseases S
  Dec 1, 2025
• Nvidia's Synopsys investment, Disney stock pops on Zootopia 2
  Yahoo Finance host Julie Hyman kicks off Yahoo Finance's Market Minute with some of the top stories of Monday's trading session, including Nvidia's (NVDA) investment in Synopsys (SNPS), Disney's (DIS) "Zootopia 2," and vaccine stock moves. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.
  Dec 1, 2025
• Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals
  The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
  Dec 1, 2025
• Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)
  The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.
  Dec 1, 2025
• Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
  Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.
  Dec 1, 2025
• Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals
  Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten vaccine-approval standards. Shares of Moderna and Novavax, which depend heavily on Covid-19 vaccine sales for revenue, fell about 6% and 3.5%, respectively. Stock in Pfizer, whose Covid-19 vaccine sales are a smaller percentage of total company revenue, ticked higher.
  Dec 1, 2025
• FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
  Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.
  Dec 1, 2025
• Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
  Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back.
  Dec 1, 2025
• S&P 500 Gains and Losses Today: Moderna Plunges; Synopsys Surges on Nvidia Deal
  Worries about regulatory headwinds weighed on vaccine producers on Monday, Dec. 1, 2025, while a chip design software maker got a boost from a partnership with an AI darling.
  Dec 1, 2025
• Moderna is the S&P 500's most shorted stock: Here's why
  President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.
  Nov 24, 2025
• Moderna is most shorted stock in S&P 500 as Americans skip immunizations
  Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its lowest level since before the...
  Nov 23, 2025
• How Recent Developments Are Rewriting the Story for Moderna
  Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The adjustment comes as revenue growth projections have been reduced from 18.75% to 10.31%, with analysts weighing bullish signals against lingering macro and operational challenges. Stay tuned to discover how investors can stay ahead of these evolving perspectives on Moderna's future...
  Nov 23, 2025
• Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
  Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire ...
  Nov 20, 2025
• Moderna to onshore drug product manufacturing to Massachusetts
  The initiative forms part of Moderna’s continued investment in US-based infrastructure.
  Nov 20, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C
  Nov 20, 2025
• Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
  Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase ...
  Nov 20, 2025
• Moderna secures $1.5B lifeline as it looks to break even in 2028
  At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth in 2027 and 2028.”
  Nov 20, 2025
• Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom
  Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.
  Nov 20, 2025
• Sector Update: Health Care Stocks Mixed in Afternoon Trading
  Health care stocks traded mixed Wednesday afternoon, with the NYSE Health Care Index up 0.1% and the
  Nov 19, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the
  Nov 19, 2025
• Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
  New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November ...
  Nov 19, 2025
• Is Moderna (MRNA) Undervalued? Examining the Latest Valuation Narrative and Investor Sentiment
  Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up the company's revenue growth alongside its ongoing net losses, especially as the biotech sector faces headwinds. See our latest analysis for Moderna. After a tough year, Moderna’s share price sits at $24.92, down more than 40% year-to-date, while its total shareholder return over the past 12 months is also in firmly negative territory. Momentum has faded as investors...
  Nov 19, 2025
• Token Security Extends Identity Governance to Autonomous AI with Launch of AI Agent Identity Lifecycle Management
  For the first time, security, IT and IAM teams can manage AI agent identities from discovery to deprovisioning to eliminate blind spots, enforce least privilege, and secure the next evolution of identity and access management NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Token Security, the leader in Agentic Identity security, today announced new AI Agent Identity Lifecycle Management capabilities which empower enterprises to discover, govern, manage, and secure the rapidly growing population of A
  Nov 19, 2025
• Alkermes escalates bidding war; US biotech risks ‘falling behind’ China
  A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.
  Nov 19, 2025
• Moderna Will Talk to Analysts on Thursday. It Needs to Stop Burning Through Cash.
  Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, investors are shifting focus to its cancer pipeline.
  Nov 19, 2025
• Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
  CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December ...
  Nov 18, 2025
• 1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm
  A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
  Nov 17, 2025
• 3 Small-Cap Stocks with Warning Signs
  Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
  Nov 13, 2025
• 5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call
  Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above Wall Street expectations for both revenue and earnings. Management attributed the outperformance to rigorous cost discipline, with CEO Stéphane Bancel noting a 34% reduction in combined cost of sales, R&D, and SG&A compared to last year. The company also cited strong market uptake of its new COVID vaccine, mNEXSPIKE, and the impact of ongoing productivity initiatives. CFO Jam
  Nov 13, 2025
• Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market
  Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market.
  Nov 13, 2025
• Stocks Gain Pre-Bell Ahead of Looming House Vote to End Government Shutdown
  The main US stock measures were pointing higher in Wednesday's premarket activity as traders await a
  Nov 12, 2025
• Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
  Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.
  Nov 11, 2025
• Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia
  Nov 11, 2025
• Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?
  In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...
  Nov 10, 2025
• Oxford Launches Regional Partnership to Drive Equitable, Innovation-Led Growth
  OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.
  Nov 10, 2025
• What Are Wall Street Analysts’ Target Price for Moderna Stock?
  Are Wall Street analysts favoring Moderna’s stock?
  Nov 10, 2025
• The Moderna, Inc. (NASDAQ:MRNA) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
  As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest quarterly results with some very strong...
  Nov 9, 2025
• MRNA Q3 Deep Dive: Cost Controls and Pipeline Progress Amid Declining COVID Vaccine Demand
  Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.
  Nov 7, 2025
• Sector Update: Health Care Stocks Ease Late Afternoon
  Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%
  Nov 7, 2025
• Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
  The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
  Nov 7, 2025
• Sector Update: Health Care Stocks Retreat Friday Afternoon
  Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se
  Nov 7, 2025
• How Recent Analyst Shifts Are Reshaping the Story for Moderna Investors
  Moderna’s stock narrative has experienced a notable shift following recent analyst updates. The consensus fair value is holding steady at $40.30, and revenue growth projections have moved sharply higher. Analysts point to evolving developments in Moderna’s clinical pipeline and a slightly increased discount rate as key drivers of the changed outlook. However, views remain mixed on the company’s near-term prospects. Stay tuned to discover how investors can monitor emerging trends that could...
  Nov 7, 2025
• Moderna Continues to Target Cash Breakeven in 2028, Morgan Stanley Says
  Moderna (MRNA) continues to target cash breakeven in 2028, banking on its ongoing cost reductions an
  Nov 7, 2025
• India Coronavirus Vaccine Research Report 2025: $1.25 Bn Market Opportunities, Competition, Forecasts 2020-2030 - Expanding Healthcare in Tier 2 and 3 Cities, and Innovations in MRNA Technology
  India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine types. Opportunities arise from vaccine diplomacy, expanding healthcare in Tier 2 and 3 cities, and innovations like mRNA technology. Challenges include vaccine hesitancy and misinformation. Indian Coronavirus Vaccine Market Indian Coronavirus Vaccine Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "India Coronavirus Vaccine Market, By Region, By Competition, Opportu
  Nov 7, 2025
• Moderna Cuts Costs As Covid Vaccine Sales Decline; Shares Rise
  Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to easily beat sales expectations.
  Nov 6, 2025
• Stock market today: Dow, S&P 500, Nasdaq fall as Nvidia leads AI trade lower, jobs jitters reignite
  The major gauges have reached a holding pattern in a volatile week with investors seeking firm news on tariffs, earnings and Tesla.
  Nov 6, 2025

MRNA Reviews

• LiquidLegend

  Dec 30, 2025

  $MRNA This company is the cool kid in science class who's always inventing new things, and honestly, we all want to sit at their lunch table!

  Buy

• FinTechFrost

  Dec 30, 2025

  $MRNA It's like the cool kid in class who always has the latest tech. You just wanna be part of that crew!

  Buy

• BearFighter

  Dec 29, 2025

  $MRNA A shot in the dark that’s losing its allure.

  Sell

• RiskVandal

  Dec 29, 2025

  $MRNA This biotech is just riding the pandemic wave—good luck after.

  Sell

• DividendJunkie

  Dec 28, 2025

  $MRNA In a race against time? Spoiler alert: they’ll lose.

  Sell

• CapitalVortex

  Dec 27, 2025

  $MRNA With all the buzz surrounding revolutionary vaccines and rising competition, the pressure is on! Will they continue to lead the charge or fall behind in the race? The stakes couldn’t be higher!

  Buy

• MoneyMage

  Dec 27, 2025

  $MRNA Catching lightning in a bottle? More like fumbling in the dark.

  Sell

• DiamondHandz

  Dec 27, 2025

  $MRNA Science on the rise, big moves coming from this crew!

  Buy

• QuantKnight

  Dec 26, 2025

  $MRNA In the race for vaccine innovation, the clock is ticking relentlessly. Every rumor about partnerships sparks a frenzy, while the fear of competition looms large over future successes.

  Buy

• DividendFrame

  Dec 26, 2025

  $MRNA A leader in pioneering messenger RNA technology, this company is reshaping the landscape of vaccine development and therapeutics. Its innovative solutions continue to hold great promise for the future of medicine.

  Buy

• ShortSavage

  Dec 26, 2025

  $MRNA With the ever-changing landscape of healthcare, this name is synonymous with innovation and risk! The pressure to deliver is immense—will it rise to the challenge?

  Buy

• CashCombo

  Dec 24, 2025

  $MRNA This stock is like the superhero of vaccines, saving the day one jab at a time! Who needs a caped crusader when you have biotech magic?

  Buy

• YOLOHold

  Dec 23, 2025

  $MRNA Pushing the limits on health tech, these innovators ain't slowing down!

  Buy

• StonkPhantom

  Dec 23, 2025

  $MRNA With innovations in healthcare racing ahead, the pressure is on to respond to unprecedented challenges. The stakes couldn't be higher, and every development could shift the landscape dramatically!

  Buy

• OptionRogue

  Dec 22, 2025

  $MRNA This company's innovative approach to vaccine development continues to capture attention and demonstrates potential for significant impact in the healthcare sector.

  Buy

• AlphaRogue

  Dec 21, 2025

  $MRNA They’re like the cool scientists at a party – everyone wants to hang out with them because they know how to make things happen!

  Buy

• AlphaVandal

  Dec 20, 2025

  $MRNA Innovation at its peak; just don’t ask about profitability.

  Sell

• TradeProtocol

  Dec 18, 2025

  $MRNA Making life-saving stuff like it's a science fair project! Just don’t mix it up with baking soda!

  Buy

• RiskProtocol

  Dec 16, 2025

  $MRNA With the world watching, their pioneering vaccine efforts have reshaped the industry. Yet, the pressure to sustain innovation in a post-pandemic world could be an uphill battle. Will they keep their edge?

  Buy

• WallStreetWraith

  Dec 16, 2025

  $MRNA Innovation or delusion? You guess.

  Sell

• OptionSpectre

  Dec 16, 2025

  $MRNA It's a vaccine company, but their stock feels sick.

  Sell

• HODLzilla

  Dec 16, 2025

  $MRNA On the front lines of innovation, they’re making moves!

  Buy

• ShortSqueezeX

  Dec 16, 2025

  $MRNA This stock has more twists and turns than a rollercoaster—hold on tight and enjoy the ride!

  Buy

• BullishSniper

  Dec 16, 2025

  $MRNA This stock is the superhero of the market—saving the day and looking good while doing it!

  Buy

• BullRunBoi

  Dec 16, 2025

  $MRNA Innovative vibes, definitely stirring up the scene!

  Buy

• RiskDriver

  Dec 16, 2025

  $MRNA This company has revolutionized the biotechnology landscape with its cutting-edge mRNA technology. Their ongoing research initiatives hold promise for addressing a range of health challenges, potentially leading to significant breakthroughs.

  Buy

• BearMarketSurvivor

  Dec 16, 2025

  $MRNA They stay flexin' with that vaccine hustle, always in demand!

  Buy

• MarketMyth

  Dec 15, 2025

  $MRNA Known for its groundbreaking work in mRNA technology, this company is at the forefront of pharmaceutical innovation. Its pipelines and collaborations are worth noting as they have the potential to redefine treatment modalities across various diseases.

  Buy

• TradeProtocol

  Dec 14, 2025

  $MRNA This stock is like a superhero for health, saving the day with shots instead of capes. Vaccines? More like VAXtastic!

  Buy

• MemeInvestor

  Dec 14, 2025

  $MRNA This stock has more hype than the latest smartphone release! Just remember, not all shiny things are golden.

  Sell

• HedgeMeNot

  Dec 14, 2025

  $MRNA In the lab, cooking up magic that could save the day.

  Buy

• EarningsEcho

  Dec 13, 2025

  $MRNA Trend severely weakening.

  Sell

• MarketNomad

  Dec 13, 2025

  $MRNA Beautiful higher-low formation developing.

  Buy

• LiquidKnight

  Dec 13, 2025

  $MRNA Downward imbalance zone expanding.

  Sell

• CryptoCoyote

  Dec 13, 2025

  $MRNA Dip reaction extremely bullish.

  Buy

• TickerFlux

  Dec 12, 2025

  $MRNA They’ve changed the world, but will they keep up the pace? As the spotlight dims, the pressure to innovate is palpable. Can they keep their edge?

  Buy

• FinTechFrost

  Dec 12, 2025

  $MRNA Broken trendline signals trouble.

  Sell

• MoonBagz

  Dec 12, 2025

  $MRNA High volatility with negative bias.

  Sell

• CashWraith

  Dec 12, 2025

  $MRNA Market confidence clearly bullish.

  Buy

• RiskReaper

  Dec 12, 2025

  $MRNA With a groundbreaking approach to vaccine technology and a strong commitment to research, this company is well-positioned to lead in the pharmaceutical industry, especially given the ongoing global health challenges.

  Buy

• StockShotz

  Dec 11, 2025

  $MRNA Massive downside risk emerging.

  Sell

• CapitalCreep

  Dec 11, 2025

  $MRNA The new darling that might just end up as yesterday's news.

  Sell

• ShortSavage

  Dec 11, 2025

  $MRNA With the spotlight constantly shifting in the world of vaccines, the pressure is immense! Can they keep the innovation going, or are they just a flash in the pan? The stakes have never been higher!

  Buy

• StonkPhantom

  Dec 11, 2025

  $MRNA Clean breakout structure forming.

  Buy

• TradeFrenzy

  Dec 11, 2025

  $MRNA Continuation to downside probable.

  Sell

• DividendGhost

  Dec 11, 2025

  $MRNA Momentum analysis extremely bullish.

  Buy

• YOLOHold

  Dec 11, 2025

  $MRNA Bearish compression near breakdown.

  Sell

• StonkPhantom

  Dec 11, 2025

  $MRNA Bulls pushing relentlessly.

  Buy

• ShortCircuit

  Dec 11, 2025

  $MRNA Higher lows building reliably.

  Buy

• ChartFang

  Dec 9, 2025

  $MRNA Renowned for its pioneering work in biotechnology, this firm continues to lead the charge in mRNA technology. Its advancements have the potential to reshape therapeutic landscapes significantly.

  Buy

• BullishBard

  Dec 9, 2025

  $MRNA This company’s got more mRNA than a science fair project on steroids! Get ready for some serious breakthroughs or just a lot of weird lab coats.

  Buy

• ShortAndProud

  Dec 9, 2025

  $MRNA Already a heavyweight, but we’re still watching for more action!

  Buy

• CapitalCrusher

  Dec 8, 2025

  $MRNA This stock is like the cool science nerd who turned into a rockstar—everyone's buzzing about it, and for good reason!

  Buy

• TradeBlitz

  Dec 8, 2025

  $MRNA Making vaccines like it’s an episode of ‘Chopped’—fast, furious, and always with a twist!

  Buy

• MarketReaper

  Dec 8, 2025

  $MRNA This stock is like that friend who always has the latest gossip. They’re in the know about science and making waves around the globe!

  Buy

• FinTechFrost

  Dec 7, 2025

  $MRNA Like a superhero saving the day, this company is in the lab saving all our bacon!

  Buy

• AlphaWave

  Dec 6, 2025

  $MRNA The pressure is mounting as expectations soar! Can they deliver groundbreaking results, or will the hype crash down? Everyone is watching!

  Buy

• MarketGlitch

  Dec 6, 2025

  $MRNA There's no room for complacency! As new breakthroughs emerge, the race is on to stay relevant. One stumble could mean losing everything built up until now!

  Sell

• AlphaVandal

  Dec 6, 2025

  $MRNA One hit wonder in a world of evolving viruses.

  Sell

• CapitalCrusher

  Dec 5, 2025

  $MRNA This stock is like a superhero for your immune system—saving the day one dose at a time and probably wearing a cape.

  Buy

• MarketMemeLord

  Dec 4, 2025

  $MRNA Got that vaccine hustle, making waves and cashing checks!

  Buy

• TradeProtocol

  Dec 4, 2025

  $MRNA This one's like a wizard with a wand—turning science into magic! Just don’t ask how they do it, it’s a secret.

  Buy

• MissionOverlord

  Dec 4, 2025

  $MRNA Market confidence extremely low.

  Sell

• TradePredator

  Dec 4, 2025

  $MRNA The hype is louder than their actual results.

  Sell

• SignalStriker

  Dec 4, 2025

  $MRNA Lots of trapped longs unloading.

  Sell

• RiskRaider

  Dec 3, 2025

  $MRNA Riding the hype wave but might wipe out any day.

  Sell

• TheMemeInvestor

  Dec 3, 2025

  $MRNA They’re the talk of the town, making waves in the game!

  Buy

• AlphaVandal

  Dec 2, 2025

  $MRNA Riding on hype instead of solid fundamentals. Good luck with that.

  Sell

• AlphaDecoder

  Dec 1, 2025

  $MRNA This company has been a trailblazer in biotechnology, particularly in mRNA technology, which has shown immense potential beyond vaccines. Its continuous research and development efforts promise to push the boundaries of medical science.

  Buy

• LiquidLegend

  Dec 1, 2025

  $MRNA This company's got the science stuff down; if they keep it up, they'll be the ones getting high fives at every vaccine party!

  Buy

• VolatileViking

  Dec 1, 2025

  $MRNA Like the coolest science project that actually works, this one has everyone's attention and for good reason—talk about innovative!

  Buy

• AlphaHawk

  Dec 1, 2025

  $MRNA They’re in the lab cooking up something big, stay tuned!

  Buy

• AlphaDruid

  Dec 1, 2025

  $MRNA The pharmaceutical buzz is electrifying, and this company is at the heart of it. Will they maintain their edge in a fast-paced environment, or will they struggle to keep up? Thrilling yet exhausting to watch!

  Buy

• FinTechFrost

  Nov 30, 2025

  $MRNA This company is like a superhero for your health – cape not included, but it’s got the power!

  Buy

• FiscalFury

  Nov 30, 2025

  $MRNA This company is about as popular as the latest TikTok dance—everyone wants in on it, especially when it comes to staying healthy!

  Buy

• LiquidityLord

  Nov 30, 2025

  $MRNA This company has been at the forefront of mRNA technology, revolutionizing vaccine development. Its innovative spirit and scientific advancements could redefine healthcare and present lucrative opportunities.

  Buy

• QuantAssault

  Nov 30, 2025

  $MRNA This company is like a scientist at a dance party—making all the right moves to keep the beat going!

  Buy

• StockShotz

  Nov 30, 2025

  $MRNA They’re basically the superheroes of healthcare, swooping in with solutions faster than you can say ‘vaccine’—cape not included!

  Buy

• EquityEnigma

  Nov 29, 2025

  $MRNA The recent news on vaccine effectiveness is stirring a whirlwind! Investors are on edge, weighing the potential breakthroughs against market volatility. What a ride!

  Buy

• TheChartCode

  Nov 29, 2025

  $MRNA This stock has the kind of hype that could make a celebrity blush. It's got the ‘vaccine’ for your portfolio!

  Buy

• EquityEnigma

  Nov 29, 2025

  $MRNA Amid the relentless race for innovation, the pressure mounts. Can they deliver the next life-saving breakthrough in time, or will competitors swoop in and steal the spotlight?

  Buy

• AlphaRogue

  Nov 29, 2025

  $MRNA This stock is like a superhero in the lab, saving the day one vaccine at a time—cape not included!

  Buy

• ShortSqueezeX

  Nov 28, 2025

  $MRNA This company is like the cool kid in school, always ahead of the game with the latest trends—except instead of fashion, it’s vaccines!

  Buy

• TendieTitan

  Nov 28, 2025

  $MRNA They're like the rockstars of the biotech world; the only thing missing is a world tour and some cool merch!

  Buy

• CapitalCarnage

  Nov 28, 2025

  $MRNA Still waiting for a breakthrough, aren't we?

  Sell

• WallStreetGrim

  Nov 27, 2025

  $MRNA This innovative firm has gained recognition for its pivotal role in mRNA technology, revolutionizing vaccine development and therapeutic solutions. Its sustained investment in research not only fuels its growth but also positions it as a leader in the biopharmaceutical field.

  Buy

• HedgeKnight

  Nov 26, 2025

  $MRNA Creating vaccines like it’s the latest TikTok dance move. They've got the moves, now let's see if they can make us groove!

  Buy

• TradeHex

  Nov 26, 2025

  $MRNA This organization continues to lead the charge in biotech innovation, showcasing a relentless commitment to advancing global health through groundbreaking research.

  Buy

• RiskRanger

  Nov 26, 2025

  $MRNA They've turned vaccines into rock stars! Who knew saving the world could come with such cool science behind it?

  Buy

• MarginMythic

  Nov 24, 2025

  $MRNA As the race for new vaccines and therapies heats up, this player's success hinges on public trust and scientific breakthroughs. It’s a thrilling, high-stakes game!

  Buy

• TradeHex

  Nov 24, 2025

  $MRNA This biotech firm remains a leader in vaccine technology, showcasing its ability to respond to global health challenges. Its ongoing research initiatives indicate a commitment to innovation and long-term success.

  Buy

• TickerTakedown

  Nov 24, 2025

  $MRNA This stock is like that one classmate who aces every test while holding a pizza—always surprising and never dull!

  Buy

• MarginBeast

  Nov 21, 2025

  $MRNA A high-flying dream that might crash back to reality.

  Sell

• OptionOverlord

  Nov 20, 2025

  $MRNA This stock is like the superhero of the pandemic—always in the lab saving the day with a brand-new cape of science!

  Buy

• MarginMarauder

  Nov 20, 2025

  $MRNA This company's all about that vaccine life! If only they could invent a shot for procrastination, we’d all be set.

  Buy

• GainsOverBrains

  Nov 18, 2025

  $MRNA Got the street buzzing, this powerhouse ain't slowing down!

  Buy

• MarketMyth

  Nov 18, 2025

  $MRNA As a frontrunner in mRNA technology, this organization's contributions to vaccine development have reshaped the pharmaceutical landscape. Its ongoing research initiatives indicate a strong potential for continued growth and impact on global health.

  Buy

• ProfitVortex

  Nov 18, 2025

  $MRNA This stock is like that one friend who always has a science project up their sleeve – sometimes it wins the science fair!

  Buy

• CapitalRush

  Nov 18, 2025

  $MRNA This innovative biotechnology company has gained significant attention for its pioneering technologies that address urgent health challenges. Its agile approach and commitment to research make it a leader in the quest for transformative treatments.

  Buy

• EquityAssault

  Nov 18, 2025

  $MRNA Another vaccine hype train with questionable stops.

  Sell

• WallStreetVandal

  Nov 17, 2025

  $MRNA The hype train derailed, and no one noticed the wreckage.

  Sell

• CapitalCreep

  Nov 17, 2025

  $MRNA Innovation is great, but what's next, more hype?

  Sell

• EquityAssault

  Nov 17, 2025

  $MRNA Good luck with those lofty expectations.

  Sell

• TickerTrickster

  Nov 16, 2025

  $MRNA This player’s got the juice, could be ready to pop off soon!

  Buy

• CashOverload

  Nov 16, 2025

  $MRNA Riding high on last year's hype won't last forever.

  Sell

• ProfitLancer

  Nov 16, 2025

  $MRNA A miracle cure? More like a mirage in the desert.

  Sell

• OptionRogue

  Nov 16, 2025

  $MRNA With groundbreaking advancements in biotechnology, this firm is poised to lead the industry with its cutting-edge research and development. Their ability to pivot and adapt plays a crucial role in their sustained relevance.

  Buy

• BuyLowBro

  Nov 15, 2025

  $MRNA This company is the ultimate 'get out of jail free' card in the pandemic Monopoly game. Trust me, everyone wants to roll those dice!

  Buy

• StonkPhantom

  Nov 14, 2025

  $MRNA With the spotlight on innovation, this player is in a race against time to revolutionize medicine! Can they keep up the pace or will they fall behind?

  Buy

• MarginMarauder

  Nov 14, 2025

  $MRNA This stock is like the cool kid wearing shades in class—everyone knows they’re about to make a big impact!

  Buy

• TradeFrenzy

  Nov 14, 2025

  $MRNA Flashy science but struggling to stay relevant.

  Sell

• BagholderPrime

  Nov 14, 2025

  $MRNA This company's contributions are like that mythical unicorn—impressive and totally magical, but can they keep the magic alive?

  Buy

• DividendHunter

  Nov 13, 2025

  $MRNA Innovation? More like a one-hit wonder on repeat.

  Sell

• VolatilityViper

  Nov 13, 2025

  $MRNA Another biotech gamble? Good luck with that rollercoaster.

  Sell

• DigitalDividend

  Nov 13, 2025

  $MRNA Talk about a glow-up! This stock went from zero to hero faster than your favorite TikTok dance challenge!

  Buy

• RiskRaider

  Nov 12, 2025

  $MRNA Riding the wave until the next big flop.

  Sell

• TheEquityEdge

  Nov 12, 2025

  $MRNA This company has pioneered groundbreaking advancements in mRNA technology, positioning itself as a leader in the biotech sector. Its innovative pipeline holds significant potential to address various infectious diseases and therapeutic needs.

  Buy

• CodeAndCapital

  Nov 11, 2025

  $MRNA This biotech champ is like your science project that actually worked—everyone’s excited and it might change the world!

  Buy

• BullishBerserker

  Nov 10, 2025

  $MRNA Every news flash turns the heat up! Is this a golden opportunity or a mirage? Your heart races with every market move, and it’s tough to keep your cool!

  Buy

• ProfitLancer

  Nov 10, 2025

  $MRNA You peaked during a pandemic; now what?

  Sell

• TradeGoblin

  Nov 10, 2025

  $MRNA Droppin’ fire with the science moves, they ain't slowing down!

  Buy

• DividendGhost

  Nov 9, 2025

  $MRNA With the pandemic shifting and new variants lurking, the pressure is intense! This company is in a race against time to stay relevant and innovative. It's a thrilling yet nerve-wracking space to watch!

  Buy

• FOMOKing

  Nov 9, 2025

  $MRNA They’re spittin’ out innovation, keepin’ the health game strong and lookin’ fresh!

  Buy

• BullRaid

  Nov 7, 2025

  $MRNA If you think this is a miracle worker, you might need a reality check.

  Sell

• ShortSurge

  Oct 18, 2025

  $MRNA tape soon theta soon volume hard level-to-level nasty dead grind steady doom vol tbh no nimble earnings soon hard flows eyes hard hands tax smart today earnings broken dead

  Sell

• ProfitVandal

  Oct 17, 2025

  $MRNA GPA falling should investors patience than my dying faster CEO apologize volume faster

  Sell

• FiscalBinary

  Oct 17, 2025

  $MRNA If charts could talk, this one would say, 'Let's ride!'.

  Sell

• BuyTheDipBro

  Oct 9, 2025

  $MRNA Riding this wave with tears of joy and a side.

  Buy

• GainsJester

  Sep 3, 2025

  $MRNA Perfect setup for disappointment right here. Who needs cardio when you hold.

  Sell

• ShortSavior

  Sep 3, 2025

  $MRNA This chart looks like it just had an energy drink.

  Sell

• FiscalEngine

  Aug 31, 2025

  $MRNA come with warning a should label

  Sell

• OptionCipher

  Aug 30, 2025

  $MRNA better show absolute my even dog clown trades

  Sell

• CodeTrader

  Aug 30, 2025

  $MRNA Riding this wave with tears of joy and a side of regret. Honestly,.

  Sell

• MarginMeme

  Aug 28, 2025

  $MRNA falling than faster even should fake to investors rally a GPA CEO apologize

  Sell

• AlgoAce

  Aug 27, 2025

  $MRNA This volume deserves a standing ovation. Momentum's cooking and I'm loving every.

  Sell

• DividendJunkie

  Aug 26, 2025

  $MRNA Rally so slow my WiFi timed out. Feels like watching a roller coaster designed by interns.

  Sell

• ProfitVortex

  Aug 23, 2025

  $MRNA dumpster fire deluxe

  Sell

• MarketPulseX

  Aug 20, 2025

  $MRNA Market mood is pure optimism today - green everywhere and everyone vibing.

  Buy

• TickerTyrant

  Aug 20, 2025

  $MRNA Technicals said no, emotions said yes - as usual. Perfect setup for disappointment.

  Sell

• CashOverload

  Apr 8, 2025

  $MRNA money hard queued heating move tape heating nimble frankly wild heater sentiment hedges spike spike soon mooning breakout

  Buy

• StockSpecter

  Nov 21, 2024

  $MRNA broken loud tape lows ouch mode flows trend heavy cat whoa feels patience today hard hurts charts whoa

  Sell

• PnLPhantom

  Nov 5, 2024

  $MRNA heating tight city clean mess soon choppy humming liquidity mode mess rough charts buzzing choppy patience

  Sell

• DividendGhost

  Aug 12, 2024

  $MRNA hands vol diamond fading tape watching hard grind my talking bleeding session frankly theta

  Sell

• ChartNomad

  Apr 7, 2024

  $MRNA spike tape money doom lower hard vol lower frankly clean sentiment energy diamond city hard macro ugly soon

  Sell

• MarginMythic

  Mar 30, 2024

  $MRNA my flows queued wild wild weak keeping bear rough soon-ish watching queued tape range range

  Sell

• CashOverload

  Mar 4, 2024

  $MRNA tight king grind patience hands now tight move humming dripping buzzing on risk grind trend nasty

  Buy